Design of the subpopulations and intermediate outcomes in copd study (SPIROMICS)

David Couper, Lisa M. LaVange, Mei Lan Han, R. Graham Barr, Eugene Bleecker, Eric A. Hoffman, Richard Kanner, Eric Kleerup, Fernando J. Martinez, Prescott G. Woodruff, Stephen Israel Rennard

Research output: Contribution to journalArticle

119 Citations (Scopus)

Abstract

Subpopulations and Intermediate Outcomes in COPD Study (SPIROMICS) is a multicentre observational study of chronic obstructive pulmonary disease (COPD) designed to guide future development of therapies for COPD by providing robust criteria for subclassifying COPD participants into groups most likely to benefit from a given therapy during a clinical trial, and identifying biomarkers/phenotypes that can be used as intermediate outcomes to reliably predict clinical benefit during therapeutic trials. The goal is to enrol 3200 participants in four strata. Participants undergo a baseline visit and three annual follow-up examinations, with quarterly telephone calls. Adjudication of exacerbations and mortality will be undertaken.

Original languageEnglish (US)
Pages (from-to)491-494
Number of pages4
JournalThorax
Volume69
Issue number5
DOIs
StatePublished - Jan 1 2014

Fingerprint

Chronic Obstructive Pulmonary Disease
Telephone
Multicenter Studies
Observational Studies
Therapeutics
Biomarkers
Clinical Trials
Phenotype
Mortality

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine

Cite this

Couper, D., LaVange, L. M., Han, M. L., Barr, R. G., Bleecker, E., Hoffman, E. A., ... Rennard, S. I. (2014). Design of the subpopulations and intermediate outcomes in copd study (SPIROMICS). Thorax, 69(5), 491-494. https://doi.org/10.1136/thoraxjnl-2013-203897

Design of the subpopulations and intermediate outcomes in copd study (SPIROMICS). / Couper, David; LaVange, Lisa M.; Han, Mei Lan; Barr, R. Graham; Bleecker, Eugene; Hoffman, Eric A.; Kanner, Richard; Kleerup, Eric; Martinez, Fernando J.; Woodruff, Prescott G.; Rennard, Stephen Israel.

In: Thorax, Vol. 69, No. 5, 01.01.2014, p. 491-494.

Research output: Contribution to journalArticle

Couper, D, LaVange, LM, Han, ML, Barr, RG, Bleecker, E, Hoffman, EA, Kanner, R, Kleerup, E, Martinez, FJ, Woodruff, PG & Rennard, SI 2014, 'Design of the subpopulations and intermediate outcomes in copd study (SPIROMICS)', Thorax, vol. 69, no. 5, pp. 491-494. https://doi.org/10.1136/thoraxjnl-2013-203897
Couper D, LaVange LM, Han ML, Barr RG, Bleecker E, Hoffman EA et al. Design of the subpopulations and intermediate outcomes in copd study (SPIROMICS). Thorax. 2014 Jan 1;69(5):491-494. https://doi.org/10.1136/thoraxjnl-2013-203897
Couper, David ; LaVange, Lisa M. ; Han, Mei Lan ; Barr, R. Graham ; Bleecker, Eugene ; Hoffman, Eric A. ; Kanner, Richard ; Kleerup, Eric ; Martinez, Fernando J. ; Woodruff, Prescott G. ; Rennard, Stephen Israel. / Design of the subpopulations and intermediate outcomes in copd study (SPIROMICS). In: Thorax. 2014 ; Vol. 69, No. 5. pp. 491-494.
@article{70f24a68f0ab411ba11264775ba55092,
title = "Design of the subpopulations and intermediate outcomes in copd study (SPIROMICS)",
abstract = "Subpopulations and Intermediate Outcomes in COPD Study (SPIROMICS) is a multicentre observational study of chronic obstructive pulmonary disease (COPD) designed to guide future development of therapies for COPD by providing robust criteria for subclassifying COPD participants into groups most likely to benefit from a given therapy during a clinical trial, and identifying biomarkers/phenotypes that can be used as intermediate outcomes to reliably predict clinical benefit during therapeutic trials. The goal is to enrol 3200 participants in four strata. Participants undergo a baseline visit and three annual follow-up examinations, with quarterly telephone calls. Adjudication of exacerbations and mortality will be undertaken.",
author = "David Couper and LaVange, {Lisa M.} and Han, {Mei Lan} and Barr, {R. Graham} and Eugene Bleecker and Hoffman, {Eric A.} and Richard Kanner and Eric Kleerup and Martinez, {Fernando J.} and Woodruff, {Prescott G.} and Rennard, {Stephen Israel}",
year = "2014",
month = "1",
day = "1",
doi = "10.1136/thoraxjnl-2013-203897",
language = "English (US)",
volume = "69",
pages = "491--494",
journal = "Thorax",
issn = "0040-6376",
publisher = "BMJ Publishing Group",
number = "5",

}

TY - JOUR

T1 - Design of the subpopulations and intermediate outcomes in copd study (SPIROMICS)

AU - Couper, David

AU - LaVange, Lisa M.

AU - Han, Mei Lan

AU - Barr, R. Graham

AU - Bleecker, Eugene

AU - Hoffman, Eric A.

AU - Kanner, Richard

AU - Kleerup, Eric

AU - Martinez, Fernando J.

AU - Woodruff, Prescott G.

AU - Rennard, Stephen Israel

PY - 2014/1/1

Y1 - 2014/1/1

N2 - Subpopulations and Intermediate Outcomes in COPD Study (SPIROMICS) is a multicentre observational study of chronic obstructive pulmonary disease (COPD) designed to guide future development of therapies for COPD by providing robust criteria for subclassifying COPD participants into groups most likely to benefit from a given therapy during a clinical trial, and identifying biomarkers/phenotypes that can be used as intermediate outcomes to reliably predict clinical benefit during therapeutic trials. The goal is to enrol 3200 participants in four strata. Participants undergo a baseline visit and three annual follow-up examinations, with quarterly telephone calls. Adjudication of exacerbations and mortality will be undertaken.

AB - Subpopulations and Intermediate Outcomes in COPD Study (SPIROMICS) is a multicentre observational study of chronic obstructive pulmonary disease (COPD) designed to guide future development of therapies for COPD by providing robust criteria for subclassifying COPD participants into groups most likely to benefit from a given therapy during a clinical trial, and identifying biomarkers/phenotypes that can be used as intermediate outcomes to reliably predict clinical benefit during therapeutic trials. The goal is to enrol 3200 participants in four strata. Participants undergo a baseline visit and three annual follow-up examinations, with quarterly telephone calls. Adjudication of exacerbations and mortality will be undertaken.

UR - http://www.scopus.com/inward/record.url?scp=84898914338&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84898914338&partnerID=8YFLogxK

U2 - 10.1136/thoraxjnl-2013-203897

DO - 10.1136/thoraxjnl-2013-203897

M3 - Article

VL - 69

SP - 491

EP - 494

JO - Thorax

JF - Thorax

SN - 0040-6376

IS - 5

ER -